Business Context and Reporting Period
Supernus Pharmaceuticals, Inc. (SUPN) filed a Current Report on Form 8-K on August 19, 2024. The filing reports a significant regulatory milestone regarding the Company's pipeline for Parkinson's disease treatment.
Key Financial Metrics
This filing is a current report regarding a specific event and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The primary material event reported is the U.S. Food and Drug Administration (FDA) acknowledgment of the resubmission of the New Drug Application (NDA) for the Company's apomorphine infusion device (SPN-830). The resubmission is intended for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson's disease. The FDA has deemed the application filed and assigned a Prescription Drug User Fee Act (PDUFA) goal date of February 1, 2025.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the Company's plans and strategies. Management notes that these statements are subject to risks and uncertainties, including those detailed in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The Company explicitly states it has no obligation to update these forward-looking statements.
Investor Verification Checklist
- Verify the PDUFA decision date of February 1, 2025, for the SPN-830 NDA.
- Review the specific indications approved or under review for the apomorphine infusion device.
- Consult the most recent Form 10-K or 10-Q for current financial health, cash runway, and debt obligations, as this 8-K does not provide financial data.
- Monitor subsequent press releases for the FDA's final action on the NDA resubmission.